Haoxi Health Technology (HAO) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Company overview and business model
Operates as a Cayman Islands holding company with business conducted in China via a wholly owned PRC subsidiary focused on online marketing solutions, primarily for healthcare clients.
Provides one-stop online marketing services, specializing in short video ads through major Chinese platforms like Toutiao, Douyin, WeChat, and Weibo.
Has served approximately 2,000 advertisers since 2018, with a majority in the healthcare sector.
Financial performance and metrics
Revenue for the six months ended December 31, 2024: $23.95 million; net loss: $232,533.
Fiscal year revenues: $48.52M (2024), $28.23M (2023), $16.16M (2022); net income: $1.29M (2024), $969,752 (2023), $244,587 (2022).
Key performance indicators include impressions, click-throughs, and conversions, with a growing advertiser base year-over-year.
Use of proceeds and capital allocation
Net proceeds from securities sales will fund business development, commercialization, working capital, general corporate purposes, and potential acquisitions or investments.
Management retains broad discretion over allocation of proceeds.
Latest events from Haoxi Health Technology
- All AGM proposals, including share consolidation and director re-elections, passed with over 99% approval.HAO
AGM 202510 Jan 2026 - Raising up to $80M on Nasdaq, the company targets healthcare marketing in China amid regulatory risks.HAO
Registration Filing16 Dec 2025 - FY2025 revenue fell 32% while net income surged to $3.88M, with ongoing regulatory and supplier risks.HAO
Q4 202412 Dec 2025 - Raising $9.09M to expand healthcare-focused digital marketing in China, but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - IPO funds will drive growth and tech investment, but regulatory and supplier risks remain high.HAO
Registration Filing29 Nov 2025 - Chinese healthcare-focused ad tech firm seeks $11.4M via Nasdaq unit offering, CEO retains control.HAO
Registration Filing29 Nov 2025 - Offering 2,093,802 units at $5.97 each, the company targets healthcare ads but faces regulatory and concentration risks.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, high regulatory risk, and CEO control define this complex offering.HAO
Registration Filing29 Nov 2025 - Rapid revenue growth, but high supplier concentration and regulatory risks; $11.4M IPO with warrants.HAO
Registration Filing29 Nov 2025